By Ricky Zipp
March 17, 2023 at 5:00 am ET
For our latest news and survey data on abortion, sign up for our global health care news and analysis brief
After hearing arguments for a lawsuit challenging the Food and Drug Administration’s decades-old approval of the abortion drug mifepristone, a Texas district court judge said he would issue a ruling as soon as possible in what has become the latest high-profile abortion fight after the fall of Roe v. Wade.
Judge Matthew Kacsmaryk, a conservative favorite, would exercise an unprecedented use of judicial power by reversing the FDA’s approval and would significantly limit access to the most common form of abortion in the United States.
As providers and pharmacies await Kacsmaryk’s decision, nearly half of Americans said they would not support a judicial ruling that would overturn the FDA’s approval of mifepristone, according to a new Morning Consult survey conducted before the hearing.
The March 11-12, 2023, survey was conducted among a representative sample of 2,200 U.S. adults, with an unweighted margin of error of plus or minus 2 percentage points.
Ricky Zipp is a data reporter at Morning Consult covering health. @zippricky